Physician profile
Maria Powers
NPI 1215451893
$5,568.93
in general payments reported to CMS, 2019-2025
27 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $444 · 2022: $1,275 · 2023: $1,164 · 2024: $1,167 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,448.81 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $423.60 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $307.32 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $245.85 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.05 | 2022-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $176.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $166.97 | 2023-2025 | Vowst, Zenpep |
| Mallinckrodt Hospital Products INC. | $163.65 | 2024-2025 | Terlivaz |
| Alnylam Pharmaceuticals INC. | $159.51 | 2023-2025 | Amvuttra, Givlaari |
| Braintree Laboratories, INC. | $144.63 | 2022-2025 | Suflave, Sutab |
| Pfizer INC. | $133.95 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $132.72 | 2022-2024 | Linzess |
| Celgene Corporation | $125.01 | 2022-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2022 | |
| Intercept Pharmaceuticals, INC. | $88.05 | 2022-2025 | Ocaliva |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.30 | 2021 | |
| Gilead Sciences, INC. | $74.97 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $69.19 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $52.42 | 2023-2024 | Omvoh |
| Ardelyx, INC. | $42.43 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $29.15 | 2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $28.59 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $25.44 | 2024 | Andexxa |
| Novo Nordisk INC | $25.11 | 2025 | Wegovy |
| Celltrion USA INC. | $24.66 | 2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $24.44 | 2025 | Adalimumab-Aacf |
| Ipsen Biopharmaceuticals, INC | $17.25 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.